By upnifty 
About Hamps Bio IPO
Hamps Bio Limited is a leading company in the ethical marketing and distribution of pharmaceutical formulation products and freeze-dried and frozen products. Established in 2007, the company operates primarily under the brands “Hamps” for pharmaceutical products and “FzyEzy” for freeze-dried and frozen foods. Hamps Bio has a diverse product portfolio that includes tablets, syrups, capsules, injectables, oils, gels, and powders, used in various therapeutic areas such as orthopedic, gynecology, dermatology, and nutrition supplements. The company distributes its pharmaceutical products through a robust network of over 50 distributors, catering to 8 states and union territories in India. Additionally, it sells its FMCG products in 6 countries, serving global markets through both direct sales and e-commerce platforms.
The company operates with a well-organized and systematic distribution model, reaching more than 8,000 doctors and 8,000 medical stores each month, generating substantial sales. Its strong presence in regions such as Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh is supported by a dedicated team of medical representatives, sales managers, and area managers. Hamps Bio partners with 16 contract manufacturers, who produce pharmaceutical products under the company’s brand name “Hamps,” ensuring strict quality controls through WHO GMP-certified facilities. Hamps Bio focuses on quality and consistency in every product it markets, and its well-established distributor network plays a key role in ensuring its widespread reach.
In 2017, Hamps Bio expanded into the freeze-dried and frozen food segment, establishing its FMCG division. The company manufactures these products at its facility in Ankleshwar, Gujarat, using advanced freeze-drying technology to preserve the natural essence of fruits, vegetables, herbs, and flowers. Hamps Bio offers two key business models in this segment: contract manufacturing for B2B clients and direct sales under its own brand “FzyEzy” for both B2B and B2C markets. The company’s FMCG products have found applications in industries such as flavor tea, soup, nutrition bars, chocolate, and ice cream. Through its presence on major e-commerce platforms like Amazon, Flipkart, and JioMart, both in India and globally, Hamps Bio has managed to expand its reach and grow its brand recognition.
As of October 31, 2024, Hamps Bio’s portfolio includes over 100 pharmaceutical products and more than 80 SKUs in the FMCG sector. The company has successfully established a solid presence in India, covering 20 states, while also expanding internationally to countries such as the USA, Canada, Europe, Australia, Africa, and the UAE. With a commitment to quality, customer satisfaction, and continuous product innovation, Hamps Bio aims to further expand its market footprint, both domestically and internationally. Leveraging its e-commerce presence, government support, and a strong distributor network, the company is well-positioned to meet the growing demand for its products and drive future growth.
Hamps Bio Limited prepares for its Initial Public Offering (IPO), the proceeds from the Fresh Issue will be allocated towards critical objectives
- Purchase of plant & machinery for FMCG division;
- Enhancing the visibility and awareness of our brand;
- General corporate purposes